Clinical Trials Logo

Clinical Trial Summary

Characterization of motor patterns with opioid agonists (codeine) ingestion, and their reversal by a peripherally acting mu-opioid receptor antagonist (Naloxegol).


Clinical Trial Description

Opioid induced constipation (OIC) is a highly prevalent condition amongst patients treated with opioids, usually for the treatment of chronic pain, both for malignant and non-malignant causes. The prevalence of constipation and other gastrointestinal side effects among chronic opioid users is 40-90%, depending on the underlying pathology, resulting in non-compliance with pain medication or a reduction in quality of life. Opioid receptors in the brain are the target for opioids to induce analgesia. Peripheral opioid receptors, mostly μ receptors, are prevalent in the enteric nervous system, and their activation underlies the occurrence of gastrointestinal side effects of opioids. Opioid-agonist binding to enteric μ receptors results in inhibition of gastric emptying, pyloric muscle tone increase, disturbance of the migrating motor complex, delayed bowel transit, decreased intestinal secretions and an elevation of anal sphincter resting pressure. Peripherally acting μ-opioid receptor antagonists are the treatment of preference for opioid-induced constipation, because they do not cross the blood-brain barrier (BBB) and so do not interfere with central analgesic effects. This peripheral mechanism is the core mechanism of Naloxegol, the most well-known agent for treating opioid overdosing. Through PEGylating, Naloxegol is a P-glycoprotein substrate with very low ability to cross the blood brain barrier (BBB). Studies have shown the ability of Naloxegol improve opioid-induced constipation in patients chronically treated with opioids, not responding to laxatives, significantly. However, the effects of opioids on colonic motor function and their reversal by opioid antagonists are poorly studied. High-resolution manometry (HRM) of the colon is a sophisticated system for studying colonic motility. Over the last few years, using this approach, it has been possible to differentiate multiple motor patterns. Research is ongoing in different functional bowel disorders (FBDs) to establish the contribution of changes in colonic motor patterns to the disease mechanism and/or symptom generation. By measuring pressures with HRM during drug administration, we want to gain insight in bowel function and motor pattern changes during treatment. HRM motor pattern analysis will help to substantiate previous findings in bowel function and OIC symptom improvements in OIC patients treated with Naloxegol.(5) We will study colonic motor patterns in healthy volunteers (HV) in a randomized, double-blind, cross-over designed trial with codeine and Naloxegol, using previously established HRM protocols and drug doses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05770960
Study type Interventional
Source Universitaire Ziekenhuizen KU Leuven
Contact
Status Completed
Phase Phase 4
Start date June 27, 2018
Completion date May 9, 2019

See also
  Status Clinical Trial Phase
Completed NCT01965652 - Long Term Safety of Naldemedine Phase 3
Completed NCT04173858 - Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
Recruiting NCT05149833 - European Study of Opioid Induced Constipation
Completed NCT01186770 - A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain Phase 3
Completed NCT02270983 - Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain Phase 2
Completed NCT00640146 - Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures Phase 2
Terminated NCT01696643 - Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Completed NCT01993940 - Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation Phase 3
Terminated NCT00399659 - Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. Phase 3
Terminated NCT01901302 - Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Withdrawn NCT00858754 - Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects Phase 4
Terminated NCT01384292 - Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain Phase 3
Completed NCT00672477 - Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Phase 4
Recruiting NCT03687268 - Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation Phase 3
Completed NCT00672139 - Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Phase 4
Terminated NCT01901341 - The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Recruiting NCT03720613 - Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain
Completed NCT01368562 - Compassionate Use Study of Methylnaltrexone N/A
Completed NCT01040637 - A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation Phase 1/Phase 2
Recruiting NCT05133076 - Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications Phase 2